Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-L-arabinofuranosidase (EC 3.2.1.55) and Beta-L-arabinofuranosidase (EC 3.2.1.185) are glycoside hydrolases that catalyze the hydrolysis of terminal non-reducing L-arabinofuranoside residues from various complex plant polysaccharides (UniProt, 2024). These enzymes are essential for the degradation of hemicelluloses such as arabinoxylan and arabinan, which are major components of plant cell walls (CAZy Database, 2024). While not produced by the human genome, these enzymes are widely distributed among plants, fungi, and bacteria, including the commensal bacteria of the human gut microbiome (PubMed: 28431250). In the gut, they play a vital role in the fermentation of dietary fibers, contributing to the production of short-chain fatty acids that support host health (PubMed: 31235547). From a therapeutic perspective, these enzymes are not traditional drug targets; however, they are significant in the development of prebiotics and the study of microbial ecology. They have also been investigated as potential targets for narrow-spectrum antimicrobials against pathogens that rely on these enzymes for nutrient acquisition (PubMed: 15653341). Additionally, they are utilized in industrial applications such as the production of biofuels, the clarification of fruit juices, and the improvement of animal feed digestibility. Because they are absent in human cells, they offer a unique biochemical pathway that can be exploited for selective microbial modulation without direct host toxicity.
These enzymes catalyze the hydrolysis of terminal non-reducing alpha-L-arabinofuranoside or beta-L-arabinofuranoside residues from arabinose-containing polysaccharides by breaking glycosidic bonds (UniProt, 2024).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-L-arabinofuranosidase and Beta-L-arabinofuranosidase (ABF).